News – Page 181 – Selby Spine

June 27, 2017

INDIANAPOLIS–(BUSINESS WIRE)–OrthoIndy and Active Implants, a company that develops orthopedic implant solutions, today announced that the first meniscus replacement procedures have been performed in Indiana. Dr. Jack Farr, orthopedic surgeon at OrthoIndy, was the first to perform the procedure on Greenwood resident Jason Scott. OrthoIndy is the only center in the state – and just one of 10 sites nationwide – participating in the VENUS (Verification of the Effectiveness of the NUsurface® System) clinical trial, which is enrolling patients with persistent knee pain after loss of meniscus cartilage to assess the safety and effectiveness of the investigational NUsurface Meniscus Implant compared to non-surgical standard of care.

The meniscus is a tissue pad between the thigh and shin bones. Once it is damaged, the meniscus has a very limited ability to heal. Over 1 million partial meniscectomies (to remove the torn portion of the meniscus) are performed in the U.S. every year, more than the total number of hip and knee replacement surgeries combined. However, many patients still experience persistent knee pain following meniscus partial excision surgery.

Scott suffered a knee injury resulting in a meniscus tear while playing high school basketball 18 years ago. This injury led the 36-year-old to undergo two partial meniscectomy surgeries on his left knee, which allowed him initially to get back to playing basketball and softball. However, the knee pain flared up over the past few years to where Scott began to experience consistent knee pain during any activity, including participating in sports, playing with his kids and simply sitting in the car for too long.

“We don’t have many surgical options for patients like Jason,” Dr. Farr said. “He is too young for knee replacement surgery and was not interested in the time it takes to recover from tibial realignment or meniscal transplant surgery. We hope NUsurface not only alleviates his pain and gets him back to his normal activities, but possibly helps him delay or avoid knee replacement surgery.”

Dr. Farr implanted the device in May 2016 through a small incision in Scott’s knee. Following a full six-week physical therapy regimen,Scott was able to gain full range of motion as well as resume daily activities. It has been one year since he received the implant and Scott’s knee continues to be stable. He has been able to play basketball again, go to concerts and sporting events, and take family vacations without worrying about knee pain.

“I feel fortunate that at the young age of 36, I’m able to receive a meniscus implant instead of living with persistent pain that could lead to an unwanted knee replacement later in life,” Scott said. “As a father of two young girls, I need to be as mobile and active as my kids are – the NUsurface implant has helped to alleviate my knee pain so I can play sports with my kids, travel with my family and get back to my athletic lifestyle.”

The NUsurface Meniscus Implant is inserted into the knee joint through a small incision and patients typically can go home on the same day of the operation. After surgery, they undergo a six-week rehabilitation program. NUsurface has been used in Europe since 2008 and Israel since 2011.

About the Clinical Trial

As part of the process to gain regulatory approval in the U.S., the VENUS (Verification of the Effectiveness of the NUsurface® System) study will enroll approximately 130 patients at orthopedic centers in the U.S., Europe and Israel. Sites in the U.S. include Indiana (Indianapolis), Massachusetts (Boston), New York (Albany, Rochester and New York), North Carolina (Durham), Ohio (Columbus), Tennessee (Memphis) and Virginia (Richmond). Participants who meet study requirements and agree to enter the trial are randomized to receive either the NUsurface device or non-surgical treatment, which is the current standard of care for patients with persistent knee pain following meniscus surgery. To be eligible for the study, participants must be between the ages of 30 and 75 and have pain after medial meniscus surgery that was performed at least six months ago. To learn more about the VENUS study, please call (844) 680-8951 or visit www.meniscus-trial.com.

About the NUsurface® Meniscus Implant

In the U.S., the NUsurface® Meniscus Implant, from Active Implants LLC, is an investigational treatment for patients with persistent knee pain following medial meniscus surgery. The NUsurface Meniscus Implant is made from medical grade plastic and, as a result of its unique materials, composite structure and design, does not require fixation to bone or soft tissue. The NUsurface device mimics the function of the natural meniscus and redistributes loads transmitted across the knee joint. It is inserted into the knee joint through a small incision, and patients typically can go home soon after the operation. After surgery, patients undergo a six-week rehabilitation program. The NUsurface device has been used clinically in Europe since 2008 and Israel since 2011.

About OrthoIndy and the OrthoIndy Hospital

Founded over 50 years ago, OrthoIndy is one of the most highly respected orthopedic practices in the Midwest. With over 70 physicians providing care to central Indiana residents from more than 10 convenient locations, OrthoIndy provides leading-edge bone, joint, spine and muscle care. OrthoIndy physicians also provide care to the Indiana Pacers, Indiana Fever, Indianapolis Indians and Dance Kaleidoscope, as well as local colleges and high schools.

Owned and operated by OrthoIndy physicians, OrthoIndy Hospital is central Indiana’s first specialty hospital with a direct focus on bone, joint, spine and muscle care and the most technologically advanced facility available for orthopedics in the Midwest. As a physician-owned hospital model, OrthoIndy Hospital’s top priorities are patient safety, satisfaction and outcomes.

Quality patient care serves as the foundation for the physician-owned and operated hospital, which is evident in the ratings received from Press Ganey Associates, Inc. From 2013 to 2016 OrthoIndy Hospital was named a Guardian of Excellence Award winner for consistently achieving the 95th percentile of performance in patient satisfaction. From 2009 to 2012, OrthoIndy Hospital was named the Summit Award Winner for sustaining the highest level of customer satisfaction for three or more consecutive years.

For more information on OrthoIndy, please call (317) 802-2000 or visit http://orthoindy.com/.

About Active Implants

Active Implants, LLC develops orthopedic implant solutions that complement the natural biomechanics of the musculoskeletal system, allowing patients to maintain or return to an active lifestyle. Active Implants is privately held with headquarters in Memphis, Tennessee. European offices are in The Netherlands, with R&D facilities in Israel. For more information, visit www.activeimplants.com.

CAUTION Investigational device. Limited by United States law to investigational use.

Contacts

Merryman Communications
Joni Ramirez, 323-532-0746
joni@merrymancommunications.com

June 27, 2017

CASTEL SAN PIETRO, Switzerland–(BUSINESS WIRE)–Hirslanden Clinique La Colline, an internationally renowned clinic in Geneva and part of the first Swiss private clinic group Hirslanden, has optimized instrument management and implant stock for its total knee replacement (TKR) procedures by introducing Medacta’s Efficiency KneePack as the new standard in its practice. This advanced solution has helped Clinique La Colline to improve its supply chain and TKR procedure workflow, reducing the resources needed to manage procedures and enabling an even stronger focus on surgeons’ needs and patients’ well being.

“I was already using Medacta’s MyKnee Patient-Specific cutting blocks, which have helped me achieve higher dependability with greater ease and comfort of use in every case,” said Dr. med. Jean-Philippe Corsat.

“The Single Use Instruments, delivered brand new and unworn every time, have been a great addition,” added Dr. med. Marc Saudan. “I didn’t have to change my technique at all; after a few cases, I was completely used to them.”

Delivered sterile and ready for use, the Efficiency KneePack is the ultimate solution to implant Medacta’s GMK^® Primary or GMK^®Sphere in a TKR procedure. The Efficiency KneePack includes femur and tibia implants, MyKnee^® Patient-Matched cutting blocks and GMK^® Efficiency single use instruments.

“Thanks to Medacta’s Efficiency KneePack, we have drastically streamlined our logistic workflow,” said André Joyeusaz, a Hirslanden Clinique La Colline logistics department representative. “Instrumentation sets and implants are delivered just a few days before surgery, limiting the stock here at the surgical unit. Everything we need is packaged together, minimizing any source of error and helping us more swiftly to manage the logistics. This is very important on busy days. Any problem related to lost or worn out instruments has been eliminated, including paperwork.”

“The first thing that I noticed was that these instruments are much lighter than the metal ones,” said Veronique Guerraz, a perioperative nurse at the clinic. “They are also very intuitive to assemble and require less thought process to set them up. I can quickly find the instruments needed at each surgical step thanks to their different colors and the organized layout. The packaged sets arrive already sterile and organized, so we do not have to check them before surgery; we can just open the blisters and start using the instruments.”

In order to facilitate the best possible outcomes, Medacta utilizes pre-operative computer-based surgical planning software to deliver exactly what is needed for the surgical procedure, including the Efficiency Instruments and implants. This minimizes inventory constraints and provides the necessary inventory to complete the specific surgical procedure.

“It is Medacta’s mission to address surgeon and hospital needs with advanced technologies that encourage patient wellbeing and healthcare system sustainability,” said Francesco Siccardi, Executive Vice President of Medacta International. “The Efficiency KneePack embodies this as it addresses pain points at every level. We believe it will become the gold standard for clinics and ambulatory surgical centers looking to optimize their resources.”

Clinique La Colline is the first center to use Medacta’s Efficiency KneePack, and other centers are now following suit.

About Medacta^® International

Medacta^® International is a world leading manufacturer of orthopedic implants, neurosurgical systems, and instrumentation. Medacta’s revolutionary approach and responsible innovation have resulted in standard of care breakthroughs in hip replacement with the AMIS^®system and total knee replacement with MyKnee^® patient matched technology. Over the last 10 years, Medacta has grown dramatically by taking a holistic approach and placing value on all aspects of the care experience from design to training to sustainability. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 30 countries.

To learn more about Medacta International, please visit: https://www.medacta.com.

Contacts

for Medacta International
Jill Bongiorni, 516-729-2250
Jill@torchcomllc.com

June 27, 2017 – Justin Juozapavicius

An Oklahoma doctor was charged Friday with second–degree murder in the overdose deaths of at least five patients from the powerful painkillers and other drugs she prescribed, often in combinations that made up an addict’s “holy trinity” of pills, state investigators said.

Oklahoma’s attorney general announced five second–degree murder counts against Regan Nichols, whose patients died while she worked at a Midwest City clinic. An Oklahoma County judge also issued a warrant for her arrest.

Nichols is among several doctors who have been criminally charged or sentenced to prison in the overdose deaths of their patients as the country desperately tries to curb its opioid epidemic. Opioids—primarily prescription painkillers and heroin—were factors in more than 33,000 deaths across the US in 2015, and opioid overdoses have more than quadrupled since 2000, according to the US Centers for Disease Control and Prevention.

“Nichols prescribed patients, who entrusted their well–being to her, a horrifyingly excessive amount of opioid medications,” Oklahoma Attorney General Mike Hunter said Friday. “Nichols’ blatant disregard for the lives of her patients is unconscionable.”

READ THE REST HERE

ALPHARETTA, Ga., June 27, 2017 /PRNewswire/ — Saince today announced the launch of PracticePerfect the much-awaited outpatient clinical documentation improvement (CDI) solution. PracticePerfect is the industry first and most comprehensive ambulatory CDI solution that includes tools for documentation improvement, risk adjustment and quality measures.

Hospitals are experiencing decreasing inpatient revenues and increasing outpatient volumes. A trend which has been continuing for the past several years. With the focus gradually shifting from inpatient to outpatient revenues, clinical documentation improvement in the outpatient setting is coming on to the center stage. At the same time, private and public insurance companies are paying increasing attention to physicians’ and hospitals’ quality scores.

PracticePerfect has the ability to automatically identify CMS and HHS Hierarchical Condition Categories (HCC) based on clinical codes, patient demographics, and other relevant criteria. Along with HCCs, the software also identifies prescription HCCs (RxHCC) and risk adjustment for End Stage Renal Disease (ESRD).

PracticePerfect also has inbuilt intelligence to identify pertinent quality measures and bring them to the attention of the physician at the point of care. This workflow will significantly improve the documentation quality at the physician level and their quality scores.

With integrated Group Practice Reporting Option (GPRO) quality measures as well, PracticePerfect will help Accountable Care Organizations (ACOs) participating in Shared Services Program in improving the quality of care they provide to their patient population.

Raghu Vir, President of Saince said, “A clinical documentation improvement tool like PracticePerfect is ideally suited to meet these evolving challenges of the healthcare industry. PracticePerfect is designed to help providers improve their clinical documentation standards, protect their reimbursements and monitor the quality of care they provide.”

The tool has attracted quite a bit of attention among healthcare providers and major hospital systems.

About Saince: Saince is a 15-year-old, award winning clinical documentation solutions and services company based in Atlanta, Ga. Saince is well recognized for its innovative solutions that help healthcare providers navigate and thrive in the fast changing healthcare industry landscape. Saince helps hospitals of all sizes and specialties – from critical access hospitals to large health systems- in saving costs, improving reimbursements and enhancing quality of care.

SOURCE Saince, Inc.

Related Links

http://www.saince.com

RAYNHAM, Mass. – June 27, 2017 – DePuy Synthes Products, Inc., part of the Johnson & Johnson Medical Devices Companies*, announced today that it has acquired Innovative Surgical Solutions, LLC, doing business as Sentio, LLC, a privately-held company based in Wixom, Michigan that markets innovative nerve localization technology for spine surgery. This acquisition underscores the DePuy Synthes and Johnson & Johnson Medical Device Companies strategy of investing in faster growing segments with technologies that are designed to help improve patient outcomes and bring value to our customers. Financial terms of the transaction have not been disclosed.

Nerve localization is important during many spine procedures, including one minimally invasive approach called lateral surgery, where temporary and permanent neurologic complications are reported in 9.4 percent and 2.5 percent of patients, respectively.[1] These complications include pain or weakness in the hip or leg due to stretching or bruising of nerves near the surgical field, and are seen despite the use of currently available nerve localization systems.¹

Most technologies on the market today rely on multiple needle electrodes in the patient’s arms or legs to locate motor nerves in the cervical and lumbar spine, and generate signals that can be problematic due to anesthesia effects, electrical interference or interpretation challenges. These systems typically require a neuromonitoring specialist to interpret the signals and guide the surgeon.

Sentio’s platform provides real-time feedback directly to the surgeon on nerve location using adhesive smart-sensors that are applied to the skin. The system can be set up by operating room personnel, does not require a neuromonitoring specialist, and has a minimal footprint in the operating room. In an animal model, Sentio’s technology detected nerve location faster than one competitive system and at lower levels of stimulation[2].

“With Sentio’s nerve localization technology, DePuy Synthes will strengthen its spine portfolio in decompression procedures as well as lateral surgery, and build a platform for future innovation in minimally invasive surgery,” said Ciro Römer, Company Group Chairman, DePuy Synthes. “The surgeon-driven approach will also help us reach more customers operating in an ambulatory surgery setting. This acquisition underscores our commitment to investing in differentiated technologies that help us reach more customers and patients around the world.”

DePuy Synthes has the second largest spine business in the world with a broad portfolio of spinal care solutions, including treatments for aging spine, less invasive surgery, scoliosis, degenerative disc disease, care delivery innovation and enabling technologies. The company intends to leverage its broad network to expand the availability of Sentio’s technology to DePuy Synthes customers globally.

About DePuy Synthes Companies
DePuy Synthes Companies, part of the Johnson & Johnson Medical Devices Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes Companies solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.

###

Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to the acquisition of Sentio. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes Products, Inc., the DePuy Synthes Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges related to integrating Sentio’s products and technologies and ensuring their continued performance and market growth; the potential that the expected benefits and opportunities related to the transaction may not be realized or may take longer to realize than expected; challenges inherent in product development, including the uncertainty of clinical outcomes and commercial success; competition, including technological advances, new products and patents attained by competitors; the ability of DePuy Synthes to successfully execute strategic plans; challenges to patents manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including under “Item 1A. Risk Factors,” its most recently filed Quarterly Report on Form 10-Q, including under the caption “Cautionary Note Regarding Forward-Looking Statements,” and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The DePuy Synthes Companies and Johnson & Johnson do not undertake to update any forward-looking statement as a result of new information or future events or developments.
* The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and cardiovascular businesses within Johnson & Johnson’s Medical Devices segment.
©DePuy Synthes 2017. All rights reserved.

[1] Joseph, J et al. Comparison of complication rates of minimally invasive transforaminal lumbar interbody fusion and lateral lumbar interbody fusion: a systematic review of the literature. Neurosurg Focus 39 (4):E4, 2015.
[2] Anderson et al (2010) An analysis of agreement between MMG vs. EMG systems for identification of nerve location during spinal procedures. NASS/Spine J.
CONTACT:
Christie Corbett
Communications
(857) 636-0211

Jason Valmore
Investor Relations
(732) 524-3709

June 27, 2017

ST. PAUL, Minn.–(BUSINESS WIRE)–Spineology, Inc. the innovator in anatomy-conserving surgery™, is excited to announce FDA clearance of the Rampart One Anterior Lumbar Interbody Fusion System.

Rampart One is designed to minimize the exposure and vascular retraction requirements associated with traditional anterior spinal fusion procedures. The system includes both standard and oblique interbody device footprints each with integrated fixation screws.

“Minimizing exposure and retraction are cornerstone elements of all Spineology anatomy conserving designs. We are very excited about this approval and look forward to entering the anterior market in the near future,” said John Booth CEO of Spineology.

“Variable angle instrumentation and integrated guides are colinear with the access, providing the surgeon the ability to keep the incision to a minimum,” said Dr. Jeremy Shore of Boston, Massachusetts.

“For instances where there is limited to no vessel mobility, the Rampart One Oblique footprint is an excellent option,” adds Dr. Clifford Tribus of Madison, Wisconsin.

Rampart One is manufactured from Invibio® PEEK-OPTIMA® HA Enhanced material. This provides an improved osteoconductive surface for bone on-growth while preserving the traditional benefits of PEEK-OPTIMA Natural including a modulus similar to bone, reduced stress shielding and artifact-free imaging.

About Spineology Inc.

Spineology Inc. provides innovative, anatomy-conserving spinal technologies for surgeons and their patients. Spineology surgical techniques conserve spinal bone, ligament and muscle tissue. Spineology is committed to increasing procedural efficiency, reducing surgical morbidity and accelerating patient recovery. Learn more at spineology.com.

Contacts

Spineology Inc.
John Booth, 651-256-8511
jbooth@spineology.com
or
Risdall
Dave Folkens, 651-286-6713
dave@risdall.com

KNOXVILLE, TN (PRWEB) JUNE 27, 2017

ChoiceSpine™, a privately-held spinal device manufacturer based in Knoxville, TN, launched its new biologics portfolio at its National Sales Meeting last week in Nashville, TN.

“We are extremely excited about the launch of our Biologics Portfolio. We wanted to come out of the gate strong so we are proud to have an offering that includes various allograft and synthetic bone graft options in addition to a full amnion offering,” commented Christy Cote, Vice President of Biologics and ChoiceSpine’s Tissue Bank Director. “We believe the addition of a biologics platform to our already strong product portfolio is an important strategic milestone.”

The Biologics product portfolio is marketed under two brands named after the Stratotanker™ plane that refuels military aircraft inflight. STRATOFUSE™ was designed to fuel fusion in spine and orthopedic surgical procedures. The STRATOFUSE brand will promote demineralized bone allograft putties and sponges, synthetic bone graft substitute putties and strips, structural allograft and allograft bone extenders. The STRATOGEN™ line will focus on a full amnion offering.

“STRATOFUSE and STRATOGEN exemplify our dedication to developing and distributing spinal products that are innovative and surgeon-focused,” said Rick Henson and Marty Altshuler, co-founders of ChoiceSpine. “We look forward to continuing to serve our surgeon customers with innovative products that deliver excellent clinical outcomes.”

Fueling their philanthropic passion, ChoiceSpine has pledged a portion of all biologics proceeds to be donated to the Smoky Mountain Service Dogs charitable organization. This non-profit organization is dedicated to helping wounded veterans. Their mission is to enhance the quality of life for veterans with disabilities by providing custom-trained, mobility-assistance service dogs.

About ChoiceSpine

ChoiceSpine is a privately-held spinal device company located in Knoxville, TN. The Company prides itself on providing excellent products and exceptional service to meet the needs of their customers. ChoiceSpine offers a breadth of innovative and surgeon-focused systems that are designed to be safe, efficient and easy-to-use. By working closely with physicians and maintaining a service-focused distribution, ChoiceSpine will continue to bring technically-superior spinal products to market.

Contact
KC Gilbert
Vice President Marketing & Professional Education
865-246-3333
kgilbert(at)choicespine.com
choicespine.com

Gosselies, Belgium, 26 June 2017; 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that the European Patent Office (EPO) has notified the Company of its intention to grant a key patent covering its first-in-class allogeneic cell therapy technology.

Once granted, the patent titled, “Osteogenic differentiation of bone marrow stem cells and mesenchymal stem cells using a combination of growth factors”, will provide legal protection to Bone Therapeutics both for the manufacturing methods and for the distinct cell type used in its allogeneic cell therapy technology. Specifically, the patent covers methods to manufacture differentiated and biologically active osteoblastic (bone-forming) cells from bone marrow stem cells, using a specific combination of growth factors, and also covers a new class of osteoblastic cells suitable for allogeneic administration to the patient.

Bone Therapeutics will now validate the patent in several countries in the European Union, potentially allowing IP protection for its allogeneic bone cell therapy platform until 2029. Patents from the same patent family have already been granted in Japan, Australia and Singapore and applications are pending in the USA, Canada, India and South Korea. ALLOB^®, Bone Therapeutics’ most advanced allogeneic bone cell therapy product, is currently being evaluated in Phase I/IIA clinical trials for delayed-union fractures and spinal fusion, for which interim results are expected in the third quarter this year.

Thomas Lienard, Chief Executive Officer of Bone Therapeutics, commented: “This notice from the European Patent Office confirms our allogeneic bone cell therapy technology is both innovative and distinctive. When granted, this European patent will significantly strengthen our IP position in the field of bone cell therapy, giving us further validation for the scientific and commercial development of our cell therapy products whilst also enhancing our position with respect to new partnerships.”

Dr. Miguel Forte, Chief Medical Officer of Bone Therapeutics, further noted: “Obtaining this patent is an important step in the development of our allogeneic bone cell therapy technology. It will provide a solid IP protection for our current work and for future technological advances, allowing us to continue our efforts to create patient-centric and commercially interesting bone cell therapy solutions.”

About Bone Therapeutics

Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.
Our technology is based on a unique, proprietary approach to bone regeneration which turns undifferentiated stem cells into “osteoblastic”, or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.
Our primary clinical focus is ALLOB^®, an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB^®, obtained from patient’s own bone marrow and currently in Phase III development for osteonecrosis and non-union fractures.

Bone Therapeutics’ cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at: www.bonetherapeutics.com.

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

COLUMBIA, Md., June 26, 2017 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (Pink Sheets:OSIR) is pleased to announce that its Board of Directors has appointed Ms. Linda Palczuk, age 55, to serve as President and CEO, effective July 10, 2017. She will stand for election to the Board of Directors at the next shareholder meeting. Ms. Palczuk had an extensive and successful 30 year career with AstraZeneca Pharmaceuticals and its legacy companies, serving in senior level commercial and general management roles, including Vice President, Mature Brands and Vice President Global Commercial Excellence, Vice President Sales & Marketing, and Vice President Sales. Afterward Ms. Palczuk was an independent consultant providing business expertise within the pharmaceutical sector.

Ms. Palczuk holds a BA in Biology from Franklin & Marshall College and a Master of Business Administration from the University of Delaware.

“I am very excited to join Osiris during this time of transformation,” said Ms. Palczuk. “I am impressed with the scientific foundation of the company and the current products and emerging pipeline that Osiris offers to patients. I look forward to working with the management team and the board of directors to successfully lead Osiris through its next stage of growth.”

“I’m delighted to welcome Linda as the CEO to Osiris to lead the organization into a new future. With her experience in the industry and leadership skills, Linda is well equipped for success. Most importantly Linda has the passion, commitment and thoughtfulness to execute on the promising technology Osiris has to bring great products to patients. Leading our mission will create value for all shareholders,” said Peter Friedli, Chairman.

Departure of Interim President & CEO.

David A. Dresner is no longer the Interim President & CEO, effective June 21, 2017. Until Ms. Palczuk’s arrival Jason Keefer the VP of Marketing for Osiris shall become the Interim President & CEO.

About Osiris Therapeutics

Osiris Therapeutics, Inc., based in Columbia, Maryland, is a leader in researching, developing and marketing cellular regenerative medicine products that improve the health and lives of patients and lower overall healthcare costs. Having developed the world’s first approved stem cell drug, Osiris works to further advance the medical field. Osiris’ research and development in biotechnology focuses on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO^4®, a viable bone matrix, Cartiform^®, a viable osteochondral allograft, Grafix^®, a cryopreserved placental membrane, and Stravix^®, a durable placental allograft. Osiris, Grafix, Cartiform, and Stravix are trademarks of Osiris Therapeutics, Inc. BIO⁴ is a registered trademark of Howmedica Osteonics Corp. More information can be found on the company’s website, www.osiris.com. (OSIR-G)

For additional information, please contact:

Diane Savoie

Osiris Therapeutics, Inc.

(443) 545-1839

OsirisPR@Osiris.com

Source: Osiris Therapeutics, Inc.

News Provided by Acquire Media

MINNEAPOLIS, June 26, 2017 /PRNewswire/ — Conventus Orthopaedics, Inc., a medical device company dedicated to revolutionizing extremity fracture treatment, today announced that Matthew Jewett will join the company on June 26, 2017 as its new Chief Executive Officer. Jewett, an experienced medical device industry executive known for building high-performing teams, developing new markets, and driving revenue growth, will also serve on the company’s Board of Directors.

“Matt’s strategic acumen and proven track record of leadership within orthopaedics made him the ideal choice to lead Conventus,” said Scott Flora, Chairman of the Board for Conventus. “We are pleased to have Matt join our company as we work to establish the Cage™ technology as the standard-of-care for the treatment of extremity fractures.”

Jewett joins Conventus following a successful career at Johnson & Johnson where he held multiple executive leadership positions within the DePuy Synthes business. “I’m excited for the opportunity to lead Conventus, a company with a truly innovative technology for the treatment of extremity fractures,” Jewett said. “The Cage technology has the potential to both positively impact patient treatment outcomes as well as reduce the cost of care for extremity fracture treatment.”

Andrew ElBardissi, MD, a surgeon and an investor at Deerfield Management, the largest investor in the company, was also appointed to Conventus’ Board of Directors. “We are thrilled to welcome Matt as a preeminent leader in orthopaedics and we are excited to help bring an innovative platform technology to market that will transform the treatment of patients with extremity fractures,” said Dr. ElBardissi. “Our recent investment, coupled with Matt’s appointment illustrates our commitment to build Conventus into an innovative and leading orthopaedic company.”

About Conventus Orthopaedics, Inc.

Conventus Orthopaedics, Inc. is an early-stage company focused on delivering a new standard of care for orthopedic fracture treatment, including complex and fragility fractures where there is a significant unmet need and a lack of treatment options. Their proprietary Cage™ technology aims to improve patient outcomes, enhance the surgeon experience, and deliver economic value to stakeholders within this market segment.

SOURCE Conventus Orthopaedics, Inc.

Newer Posts

Older Posts

Search

3 days / 6 sessions
Current Issues in Spine

OrthoIndy Performs First Meniscus Replacements in Indiana with NUsurface® Implant

Contacts

Hirslanden Clinique La Colline Adopts Medacta’s Efficiency KneePack: the New Gold Standard in Resource Optimization and Knee Replacement Procedure Management

Contacts

Oklahoma doctor charged in opioid deaths of 5 patients

As hospitals’ revenues shift from inpatient to outpatient setting, Saince’s new tool improves documentation quality

Related Links

DePuy Synthes Announces Acquisition of Sentio, LLC to Enable Innovation in Minimally Invasive Spine Surgery

Spineology® Announces FDA Clearance of Rampart One™ Anterior Lumbar Interbody Fusion System

Contacts

ChoiceSpine Launches Biologics Portfolio at National Sales Meeting

Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform

Osiris Appoints Linda Palczuk to serve as its President & CEO

Conventus Orthopaedics Strengthens Company Leadership

STAR Ankle Joint Replacements Last Long Term and Provide Relief for Patients

Medacta USA’s Spine Division Begins 2017 with Key Appointment, Significant Growth

Spinal Stabilization Technologies Announces Start of LOPAIN 2 Clinical Trial in South America for Lumbar Degenerative Disc Disease

$250K Pediatric Device Competition Now Accepting Proposals

First Single-Use Rigid Endoscope to be Demonstrated at AAOS